Sg3 Management, LLC Novavax Inc Transaction History

Sg3 Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$36.28 - $75.29 $36,280 - $75,290	-1,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$69.73 - $142.9 $34,865 - $71,450	500 Added 100.0%	1,000 $74,000
Q4 2021 Feb 15, 2022	BUY	$134.56 - $217.97 $67,280 - $108,985	500 New	500 $72,000
Q3 2021 Nov 15, 2021	SELL	$177.8 - $270.58 $355,600 - $541,160	-2,000 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$121.0 - $257.67 $242,000 - $515,340	2,000 New	2,000 $425,000
Q1 2021 May 17, 2021	SELL	$112.98 - $319.93 $225,960 - $639,860	-2,000 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$78.74 - $139.5 $39,370 - $69,750	-500 Reduced 20.0%	2,000 $223,000
Q3 2020 Nov 13, 2020	BUY	$79.44 - $178.51 $198,600 - $446,275	2,500 New	2,500 $271,000

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $662M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.